Bristol-Myers Squibb ( NYSE: BMY ) shares traded in the green on Tuesday, breaking six straight days of losses. Stock closed up 0.17% at $42.
34. BMY has fallen 35.3% in the last 12 months and 13.
5% in the last one month. YTD, the stock is trading below the broader S&P 500 market which rose 11.57% as compared to BMY’s YTD loss of 17.
6%. Looking at Seeking Alpha's Quant Ratings, this New Jersey based company has a Hold rating with a score of 2.94 out of 5.
When it comes to Wall Street analysis, 19 out of 26 analysts recommend a Hold, 3 rate it as a Strong Buy, 3 rate it as a Buy, and 1 rates it as a Strong Sell. Seeking Alpha analysts have a Buy rating on the company. According to SA analyst Philipp Stuelcken, “The company made several acquisitions, increasing its debt levels, but the long-term outlook remains uncertain.
Mid-term outlook indicates that there will be many years without growth. Valuation seems low enough to rate it still a strong buy.” BMY stock fell last month despite Q1 results exceeding expectations amid headwinds to key components in its growth portfolio dominated by its cancer therapy Opdivo.
More on Bristol-Myers Squibb Company Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript) Bristol-Myers Squibb: A Lost Decade? Bristol-Myers, Sanofi liability in Hawaii Plavix litigation tops $900M Bristol-Myers says.
